This content is from:APP亚博娱乐
Sorbent Secures $36M In VC Funding
Sorbent Therapeutics has closed a $36 million Series B financing round led by new investor Novartis Venture Funds.
Sorbent Therapeuticshas closed a $36 million Series B financing round led by new investorNovartis Venture Funds. The firm’s existing investorsSofinnova Ventures,ARCH Venture Partners,CMEA CapitalandAgeChemalsoparticipated.
The deal brings the total proceeds of the biopharmaceutical company’s second funding round to $53 million.Markus Goebel,managing directorofNovartis Venture Funds, has joined Sorbent’s board of directors as part of the transaction. The funds will be used to complete a mid-stage program for its lead congestive heart failure drug and to add a few employees.
Click here for the release fromSorbent.